Premium
Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized, placebo‐controlled trial
Author(s) -
Uzel Barbara Pontes Cerqueira,
Takano Gustavo Henrique Soares,
Chartuni Juliana Cabral Nunes,
Cesetti Mariana Vicente,
Gavioli Camila Fátima Biancardi,
Lemes André Moreira,
Costa Izelda Maria Carvalho
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14622
Subject(s) - minoxidil , medicine , placebo , randomized controlled trial , dermatology , alternative medicine , pathology
Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined. The objective of this study was to evaluate the efficacy and safety of intradermal injections with 0.5% minoxidil for the management of female androgenetic alopecia in a randomized, placebo‐controlled trial. A total of 54 women diagnosed with female androgenetic alopecia were divided into two groups: one group received intradermal injections of 0.5% minoxidil, and the other received 0.9% saline. Biopsy, trichogram, Trichoscan (Tricholog GmbH, Freiburg, Germany), and self‐assessment findings were used to evaluate the outcomes of treatment with minoxidil. In the treated group, there was a significant increase in the terminal‐to‐vellus hair ratio ( P < .001) and in the percentage of anagen hairs ( P = .048) and an improvement in hair loss and volume ( P = .021 and P = .028, respectively). These results show that intradermal injections with minoxidil were more effective than placebo ( P < .001) in the treatment of female androgenetic alopecia with a good safety profile.